/
CRDF
$1.27+$0.02 (+1.60%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$85.5M
68M shares
52-week range
$1.16 – $4.56
3% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-5.38
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $378.0K | $244.6K | $366.0K | $359.0K | $386.0K | $488.0K | $683.0K | $593.0K |
| Cost of revenue | $597.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$219.0K | $244.6K | $366.0K | $359.0K | $386.0K | $488.0K | $683.0K | $593.0K |
| Gross margin | -57.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| R&D | $8.2M | $11.2M | $11.2M | $17.4M | $27.1M | $32.9M | $36.9M | $35.3M |
| Operating income | −$17.1M | −$16.7M | −$19.1M | −$28.9M | −$39.9M | −$45.4M | −$48.7M | −$49.0M |
| EBITDA | −$15.7M | −$15.9M | −$18.8M | −$27.8M | −$38.5M | −$41.0M | −$45.0M | −$44.9M |
| Net income | −$16.5M | −$16.4M | −$19.3M | −$28.3M | −$38.7M | −$41.4M | −$45.4M | −$45.9M |
| Net margin | -4354.8% | -6709.7% | -5275.1% | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| EPS (diluted) | -7.06 | -2.70 | -1.08 | -0.73 | -0.89 | -0.93 | -0.95 | -0.69 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $244000 | $-0.68 | $-0.80–$-0.43 | 6 |
| 2027 | $189286 | $-0.82 | $-0.92–$-0.59 | 5 |
| 2028 | $230000 | $-1.13 | $-1.40–$-0.74 | 6 |
| 2029 | $102M | $-0.67 | $-1.15–$-0.21 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.01
Price
$1.27
Implied downside
-99%
Peer comparison
Cardiff Oncology, Inc. Common Stock
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
www.cardiffoncology.com- Employees
- 31
- IPO / List date
- May 22, 1997
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds CRDF.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 101,253 | $164.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2019-02-20 | 1-for-6reverse |
| 2018-06-04 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded CRDF yet.
